A New Treatment Strategy for Parkinson's Disease through the Gut–Brain Axis
Molecular communications in the gut–brain axis, between the central nervous system and the gastrointestinal tract, are critical for maintaining healthy brain function, particularly in aging. Epidemiological analyses indicate type 2 diabetes mellitus (T2DM) is a risk factor for neurodegenerative diso...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2017-09-01
|
Series: | Cell Transplantation |
Online Access: | https://doi.org/10.1177/0963689717721234 |
id |
doaj-4a5f9b394d4f4e2b86dcc770948be469 |
---|---|
record_format |
Article |
spelling |
doaj-4a5f9b394d4f4e2b86dcc770948be4692020-11-25T03:32:43ZengSAGE PublishingCell Transplantation0963-68971555-38922017-09-012610.1177/0963689717721234A New Treatment Strategy for Parkinson's Disease through the Gut–Brain AxisDong Seok Kim0Ho-Il Choi1Yun Wang2Yu Luo3Barry J. Hoffer4Nigel H. Greig5 Drug Design and Development Section, Translational Gerontology Branch, Intramural Research Program, National Institute on Aging, National Institutes of Health, Baltimore, MD, USA. Peptron Inc., Yuseong-gu, Daejeon, Republic of Korea Center for Neuropsychiatric Research, National Health Research Institutes, Zhunan, Miaoli County, Taiwan Department of Neurosurgery, Case Western Reserve University School of Medicine, Cleveland, OH, USA Department of Neurosurgery, Case Western Reserve University School of Medicine, Cleveland, OH, USA Drug Design and Development Section, Translational Gerontology Branch, Intramural Research Program, National Institute on Aging, National Institutes of Health, Baltimore, MD, USA.Molecular communications in the gut–brain axis, between the central nervous system and the gastrointestinal tract, are critical for maintaining healthy brain function, particularly in aging. Epidemiological analyses indicate type 2 diabetes mellitus (T2DM) is a risk factor for neurodegenerative disorders including Alzheimer's disease (AD) and Parkinson's diseases (PD) for which aging shows a major correlative association. Common pathophysiological features exist between T2DM, AD, and PD, including oxidative stress, inflammation, insulin resistance, abnormal protein processing, and cognitive decline, and suggest that effective drugs for T2DM that positively impact the gut–brain axis could provide an effective treatment option for neurodegenerative diseases. Glucagon-like peptide-1 (GLP-1)-based antidiabetic drugs have drawn particular attention as an effectual new strategy to not only regulate blood glucose but also decrease body weight by reducing appetite, which implies that GLP-1 could affect the gut–brain axis in normal and pathological conditions. The neurotrophic and neuroprotective effects of GLP-1 receptor (R) stimulation have been characterized in numerous in vitro and in vivo preclinical studies using GLP-1R agonists and dipeptidyl peptidase-4 inhibitors. Recently, the first open label clinical study of exenatide, a long-acting GLP-1 agonist, in the treatment of PD showed long-lasting improvements in motor and cognitive function. Several double-blind clinical trials of GLP-1R agonists including exenatide in PD and other neurodegenerative diseases are already underway or are about to be initiated. Herein, we review the physiological role of the GLP-1R pathway in the gut–brain axis and the therapeutic strategy of GLP-1R stimulation for the treatment of neurodegenerative diseases focused on PD, for which age is the major risk factor.https://doi.org/10.1177/0963689717721234 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Dong Seok Kim Ho-Il Choi Yun Wang Yu Luo Barry J. Hoffer Nigel H. Greig |
spellingShingle |
Dong Seok Kim Ho-Il Choi Yun Wang Yu Luo Barry J. Hoffer Nigel H. Greig A New Treatment Strategy for Parkinson's Disease through the Gut–Brain Axis Cell Transplantation |
author_facet |
Dong Seok Kim Ho-Il Choi Yun Wang Yu Luo Barry J. Hoffer Nigel H. Greig |
author_sort |
Dong Seok Kim |
title |
A New Treatment Strategy for Parkinson's Disease through the Gut–Brain Axis |
title_short |
A New Treatment Strategy for Parkinson's Disease through the Gut–Brain Axis |
title_full |
A New Treatment Strategy for Parkinson's Disease through the Gut–Brain Axis |
title_fullStr |
A New Treatment Strategy for Parkinson's Disease through the Gut–Brain Axis |
title_full_unstemmed |
A New Treatment Strategy for Parkinson's Disease through the Gut–Brain Axis |
title_sort |
new treatment strategy for parkinson's disease through the gut–brain axis |
publisher |
SAGE Publishing |
series |
Cell Transplantation |
issn |
0963-6897 1555-3892 |
publishDate |
2017-09-01 |
description |
Molecular communications in the gut–brain axis, between the central nervous system and the gastrointestinal tract, are critical for maintaining healthy brain function, particularly in aging. Epidemiological analyses indicate type 2 diabetes mellitus (T2DM) is a risk factor for neurodegenerative disorders including Alzheimer's disease (AD) and Parkinson's diseases (PD) for which aging shows a major correlative association. Common pathophysiological features exist between T2DM, AD, and PD, including oxidative stress, inflammation, insulin resistance, abnormal protein processing, and cognitive decline, and suggest that effective drugs for T2DM that positively impact the gut–brain axis could provide an effective treatment option for neurodegenerative diseases. Glucagon-like peptide-1 (GLP-1)-based antidiabetic drugs have drawn particular attention as an effectual new strategy to not only regulate blood glucose but also decrease body weight by reducing appetite, which implies that GLP-1 could affect the gut–brain axis in normal and pathological conditions. The neurotrophic and neuroprotective effects of GLP-1 receptor (R) stimulation have been characterized in numerous in vitro and in vivo preclinical studies using GLP-1R agonists and dipeptidyl peptidase-4 inhibitors. Recently, the first open label clinical study of exenatide, a long-acting GLP-1 agonist, in the treatment of PD showed long-lasting improvements in motor and cognitive function. Several double-blind clinical trials of GLP-1R agonists including exenatide in PD and other neurodegenerative diseases are already underway or are about to be initiated. Herein, we review the physiological role of the GLP-1R pathway in the gut–brain axis and the therapeutic strategy of GLP-1R stimulation for the treatment of neurodegenerative diseases focused on PD, for which age is the major risk factor. |
url |
https://doi.org/10.1177/0963689717721234 |
work_keys_str_mv |
AT dongseokkim anewtreatmentstrategyforparkinsonsdiseasethroughthegutbrainaxis AT hoilchoi anewtreatmentstrategyforparkinsonsdiseasethroughthegutbrainaxis AT yunwang anewtreatmentstrategyforparkinsonsdiseasethroughthegutbrainaxis AT yuluo anewtreatmentstrategyforparkinsonsdiseasethroughthegutbrainaxis AT barryjhoffer anewtreatmentstrategyforparkinsonsdiseasethroughthegutbrainaxis AT nigelhgreig anewtreatmentstrategyforparkinsonsdiseasethroughthegutbrainaxis AT dongseokkim newtreatmentstrategyforparkinsonsdiseasethroughthegutbrainaxis AT hoilchoi newtreatmentstrategyforparkinsonsdiseasethroughthegutbrainaxis AT yunwang newtreatmentstrategyforparkinsonsdiseasethroughthegutbrainaxis AT yuluo newtreatmentstrategyforparkinsonsdiseasethroughthegutbrainaxis AT barryjhoffer newtreatmentstrategyforparkinsonsdiseasethroughthegutbrainaxis AT nigelhgreig newtreatmentstrategyforparkinsonsdiseasethroughthegutbrainaxis |
_version_ |
1724566400438108160 |